Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients: Anti-HBV PreS1 antibody. Issue 3 (March 2022)
- Record Type:
- Journal Article
- Title:
- Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients: Anti-HBV PreS1 antibody. Issue 3 (March 2022)
- Main Title:
- Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients
- Authors:
- Hatooka, Haruna
Shimomura, Yumi
Imamura, Michio
Teraoka, Yuji
Morio, Kei
Fujino, Hatsue
Ono, Atsushi
Nakahara, Takashi
Murakami, Eisuke
Yamauchi, Masami
Kawaoka, Tomokazu
Makokha, Grace Naswa
Miki, Daiki
Tsuge, Masataka
Hiramatsu, Akira
Abe-Chayama, Hiromi
Hayes, C. Nelson
Aikata, Hiroshi
Tanaka, Shinji
Chayama, Kazuaki - Abstract:
- Highlights: The preS1 region plays an essential role in hepatitis B virus (HBV) infection. Construction of an antibody against preS1 and an ELISA system capable of measuring serum HBV preS1 levels. PreS1 levels are correlated with HBV markers such as HBsAg, HBcrAg and HBV DNA. PreS1 levels may serve as a novel tool to predict the need for antiviral therapy in HBeAg-negative HBV-infected patients. Summary: Objectives: The preS1 region plays an essential role in hepatitis B virus (HBV) infection. We construct an antibody that binds to preS1 and a measurement system for serum preS1 in chronic HBV-infected patients. Methods: Hybridoma clones that produce anti-preS1 antibodies were obtained by the iliac lymph node method. Epitope mapping was conducted, and an enzyme-linked immunosorbent assay (ELISA)-based method was developed. Using this ELISA system, serum preS1 levels were measured in 200 chronic HBV-infected patients. Results: Eight types of hybridomas were obtained, of which antibody 3–55 using amino acids 38–47 as the epitope showed high binding affinity to preS1. Serum preS1 levels measured by ELISA using 3–55 antibody were correlated with HBsAg, HBcrAg and HBV DNA levels. Among HBeAg-negative patients without antiviral therapeutic objective (HBV DNA <3.3 log IU/mL or alanine aminotransferase ≤30 U/L), preS1 was significantly higher in subjects who had progressed to the point of requiring antiviral therapy compared to subjects who had maintained their status for theHighlights: The preS1 region plays an essential role in hepatitis B virus (HBV) infection. Construction of an antibody against preS1 and an ELISA system capable of measuring serum HBV preS1 levels. PreS1 levels are correlated with HBV markers such as HBsAg, HBcrAg and HBV DNA. PreS1 levels may serve as a novel tool to predict the need for antiviral therapy in HBeAg-negative HBV-infected patients. Summary: Objectives: The preS1 region plays an essential role in hepatitis B virus (HBV) infection. We construct an antibody that binds to preS1 and a measurement system for serum preS1 in chronic HBV-infected patients. Methods: Hybridoma clones that produce anti-preS1 antibodies were obtained by the iliac lymph node method. Epitope mapping was conducted, and an enzyme-linked immunosorbent assay (ELISA)-based method was developed. Using this ELISA system, serum preS1 levels were measured in 200 chronic HBV-infected patients. Results: Eight types of hybridomas were obtained, of which antibody 3–55 using amino acids 38–47 as the epitope showed high binding affinity to preS1. Serum preS1 levels measured by ELISA using 3–55 antibody were correlated with HBsAg, HBcrAg and HBV DNA levels. Among HBeAg-negative patients without antiviral therapeutic objective (HBV DNA <3.3 log IU/mL or alanine aminotransferase ≤30 U/L), preS1 was significantly higher in subjects who had progressed to the point of requiring antiviral therapy compared to subjects who had maintained their status for the preceding three years ( p <0.01). Conclusions: We constructed an antibody against preS1 and an ELISA system capable of measuring serum preS1 levels. PreS1 may serve as a novel tool to predict the need for antiviral therapy in HBeAg-negative HBV-infected patients. … (more)
- Is Part Of:
- Journal of infection. Volume 84:Issue 3(2022)
- Journal:
- Journal of infection
- Issue:
- Volume 84:Issue 3(2022)
- Issue Display:
- Volume 84, Issue 3 (2022)
- Year:
- 2022
- Volume:
- 84
- Issue:
- 3
- Issue Sort Value:
- 2022-0084-0003-0000
- Page Start:
- 391
- Page End:
- 399
- Publication Date:
- 2022-03
- Subjects:
- HB virusepatitis B virus -- Hybridoma -- PreS1 -- Hepatitis B e antigen -- Large hepatitis B surface proteins
ALT alanine aminotransferase -- AUC area under the curve -- cccDNA covalently closed circular DNA -- CDR complementarity determining region -- CHB chronic hepatitis B -- CV coefficient of variance -- ELISA enzyme-linked immunosorbent assay -- HBcrAg hepatitis B core-related antigen -- HBeAg hepatitis B e antigen -- HBsAg hepatitis B surface antigen -- HBsAb hepatitis B surface antibody -- HBV hepatitis B virus -- HCC hepatocellular carcinoma -- IC inactive carrier -- LC liver cirrhosis -- LHBs large hepatitis B surface proteins -- MHBs middle hepatitis B surface proteins -- ROC receiver operating characteristic -- SHBs small hepatitis B surface proteins
Infection -- Periodicals
Bacterial Infections -- Periodicals
Communicable Diseases -- Periodicals
Electronic journals
616.905 - Journal URLs:
- http://www.idealibrary.com/links/toc/jinf/ ↗
http://www.harcourt-international.com/journals ↗
http://www.sciencedirect.com/science/journal/01634453 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/01634453 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/01634453 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.jinf.2021.12.025 ↗
- Languages:
- English
- ISSNs:
- 0163-4453
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5006.690000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 21005.xml